Soligenix Inc. said it has received a positive recommendation from the independent Data Monitoring Committee to continue enrolling into the company’s phase III “Fluorescent Light Activated Synthetic Hypericin” study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
